Jeffrey James, DO
Gynecologic Oncology · Lone Tree, CONPI 1316144868
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (34.9%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 71.4% of it on its own, with 38 other manufacturers making up the rest. 2025 is the largest year on record at $69,294, more than ten times the $2,398 reported in 2019. Among gynecologic oncology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 388 payments — averaging $451.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$125K
- Conmed Corporation$9K
- Virtual Incision Corporation$8K
- AbbVie$7K
- GSK$7K
- Medical Device Business Services, Inc.$5K
- plus $13K from 33 others
What the payments were for
- Consulting fees$36,25921%
- Speaking & faculty fees$59,09534%
- Travel & lodging$5,2123%
- Food & beverage$13,1378%
- Education$61,20035%
- Gifts$2090%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 178 | $124,955 |
| Conmed Corporation | 8 | $8,647 |
| Virtual Incision Corporation | 6 | $8,370 |
| AbbVie | 18 | $7,395 |
| GSK | 37 | $7,191 |
| Medical Device Business Services, Inc. | 3 | $5,441 |
| Johnson & Johnson | 6 | $4,080 |
| Pfizer | 3 | $2,265 |
| Tempus AI, Inc | 9 | $2,173 |
| AstraZeneca | 31 | $1,404 |
| Genmab U.S., Inc. | 25 | $897 |
| On Target Laboratories, Inc | 1 | $750 |
| Merck | 13 | $352 |
| Eisai Inc. | 8 | $269 |
| Clovis Oncology, Inc. | 8 | $111 |
| Seagen Inc. | 1 | $100 |
| Hologic Sales And Service, LLC | 4 | $83 |
| Myriad Genetic Laboratories, Inc. | 2 | $71 |
| Davol Inc. | 1 | $61 |
| Astellas Pharma US Inc | 2 | $47 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $47 |
| Tesaro, Inc. | 2 | $38 |
| Pharmaand GmbH | 2 | $37 |
| Avanos Medical | 1 | $37 |
| Immunogen, Inc. | 2 | $37 |
| Teleflex LLC | 2 | $29 |
| Aroa Biosurgery Incorporated | 1 | $25 |
| Cumberland Pharmaceuticals, Inc. | 1 | $21 |
| Boston Scientific | 1 | $20 |
| Smith+Nephew | 1 | $20 |
| Integra Lifesciences Corporation | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Innovation Technologies Inc | 1 | $16 |
| AMAG Pharmaceuticals, Inc. | 1 | $15 |
| Meditrina | 1 | $13 |
| Amgen | 1 | $12 |
| Dysis Medical, Inc. | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$97,040
- DA VINCI SP$25,000
- Mira!$8,134
- Elahere$6,877
- AIRSEAL$6,250
- ETHICON$5,544
- VISTASEAL$5,438
- SURGIFLO Hemostatic Matrix$5,438
- SURGICEL NU-KNIT$3,880
- JEMPERLI$2,600
- TIVDAK$2,394
- Helix$2,250
- ZEJULA$2,131
- LYNPARZA$1,002
- DAVINCI XI$1,000
- Cytalux$750
- KEYTRUDA$118
- LENVIMA$112
How this compares
$175,111 in reported general payments places this provider in the 95th percentile of 28 gynecologic oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LynparzaOlaparib | 29 | $348,216 |
| EliquisApixaban | 30 | $24,539 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 36 | $447 |
| Letrozole | 12 | $312 |
| Prochlorperazine Maleate | 26 | $232 |
| Duloxetine Hcl | 13 | $227 |
| Potassium Chloride | 23 | $153 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaLynparza | $1,404 | $348,21629 claims |
| PfizerEliquis | $2,265 | $24,53930 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 28 gynecologic oncology providers in Colorado.
Other gynecologic oncology in Lone Tree
- Susan ReadLone Tree$5K
- Bradley CorrAurora$70K
- Robin LacourGreeley$64K
- John CurtinDenver$42K
- Saketh GuntupalliAurora$39K
- Kevin DavisEnglewood$32K
- Glenn BigsbyLittleton$12K
- Carolyn LefkowitsAurora$11K
- Kian BehbakhtAurora$10K
- Christine WalshAurora$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.